Last Updated : May 6, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
Brand Name | Generic Name | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received Sort ascending | Date Recommendation Issued |
---|---|---|---|---|---|---|
Spriafil | Posaconazole | Aspergillus and Candida infections | Do not list | Complete | ||
Altace HCT | Ramipril/hydrochlorothiazide | Hypertension | List | Complete | ||
Champix | Varenicline tartrate | Smoking-cessation | List with clinical criteria and/or conditions | Complete | ||
Zytram XL | Tramadol hydrochloride | Pain, acute | Do not list | Complete | ||
Sativex | Delta-9-tetrahydrocannabinol/cannabidiol | Pain, Neuropathic (adjunctive) in MS. | Do not list | Complete | ||
Somatuline Autogel | Lanreotide acetate | Acromegaly | List in a similar manner to other drugs in class | Complete | ||
Prexige | Lumiracoxib | Osteoarthritis (Knee) | Do not list | Complete | ||
Baraclude | Entecavir | Hepatitis B (chronic) | List with clinical criteria and/or conditions | Complete | ||
Sebivo | Telbivudine | Hepatitis B (chronic) | Do not list | Complete | ||
Humira | Adalimumab | Ankylosing spondylitis (AS) | List with clinical criteria and/or conditions | Complete |